More than 40 million euro will be granted by the EIB to the society Isotopen Technologien München AG. These funds will facilitate the development of innovative cancer treatments.

ITM will use this financing to invest in research and development of therapies addressing a range of cancers, such as neuroendocrine tumors and bone metastases. The ground-breaking therapies will benefit patients throughout Europe and worldwide. The loan is backed by the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe. 

As of December 2019, the Investment Plan has mobilised €458.8 billion of investment across the EU and supported more than one million start-ups and small and medium businesses. Last week, the Commission launched an EU-wide public consultation on Europe’s Beating Cancer Plan.